Drug Profile
Research programme: metabolic and cardiovascular disease therapeutics - Syndexa Pharmaceuticals
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Syndexa Pharmaceuticals Corporation
- Class Small molecules
- Mechanism of Action Cytokine receptor antagonists; Fatty acid inhibitors; Fatty acid-binding protein inhibitors; Inflammation mediator inhibitors; JNK mitogen-activated protein kinase inhibitors; Nuclear protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA